<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848208</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-CYT-08</org_study_id>
    <secondary_id>2018-003344-22</secondary_id>
    <nct_id>NCT03848208</nct_id>
  </id_info>
  <brief_title>A Single Dose-escalation Study of Cytisine in Adult Smokers</brief_title>
  <official_title>A Phase I, Double-blind, Randomized, Placebo-controlled, Single Dose-escalation Study to Evaluate the Tolerability and Safety of Cytisine in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
        1. To assess the tolerability and safety of cytisine as a single oral dose.&#xD;
&#xD;
        2. To define the Cmax levels associated to the occurrence of dose-limiting adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation</measure>
    <time_frame>From first dose of study drug through Day 6</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have to have a causal relationship with the treatment. A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; or is an important medical event which requires medical intervention to prevent one of the above. Treatment emergent events are those that occurred after the first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time to Occurrence of Cmax (Tmax)</measure>
    <time_frame>Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Cytisine 6.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Cytisine 9.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Cytisine 12.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Cytisine 15.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Cytisine 18.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Cytisine 21.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Cytisine 24.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: Cytisine 27.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: Cytisine 30.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytisine</intervention_name>
    <description>cytisine film-coated oral tablet</description>
    <arm_group_label>Cohort 1: Cytisine 6.0 mg</arm_group_label>
    <arm_group_label>Cohort 2: Cytisine 9.0 mg</arm_group_label>
    <arm_group_label>Cohort 3: Cytisine 12.0 mg</arm_group_label>
    <arm_group_label>Cohort 4: Cytisine 15.0 mg</arm_group_label>
    <arm_group_label>Cohort 5: Cytisine 18.0 mg</arm_group_label>
    <arm_group_label>Cohort 6: Cytisine 21.0 mg</arm_group_label>
    <arm_group_label>Cohort 7: Cytisine 24.0 mg</arm_group_label>
    <arm_group_label>Cohort 8: Cytisine 27.0 mg</arm_group_label>
    <arm_group_label>Cohort 9: Cytisine 30.0 mg</arm_group_label>
    <other_name>Tabex</other_name>
    <other_name>cytisinicline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo oral tablet</description>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_label>Cohort 3: Placebo</arm_group_label>
    <arm_group_label>Cohort 4: Placebo</arm_group_label>
    <arm_group_label>Cohort 5: Placebo</arm_group_label>
    <arm_group_label>Cohort 6: Placebo</arm_group_label>
    <arm_group_label>Cohort 7: Placebo</arm_group_label>
    <arm_group_label>Cohort 8: Placebo</arm_group_label>
    <arm_group_label>Cohort 9: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet ALL of the following criteria to be eligible for inclusion into the&#xD;
        study:&#xD;
&#xD;
          1. Free written informed consent prior to any procedure required by the study.&#xD;
&#xD;
          2. Male or female subjects, age ≥18 years, at the time of signing the informed consent.&#xD;
&#xD;
          3. Current daily cigarette smokers (averaging at least 10 cigarettes per day in the past&#xD;
             30 days).&#xD;
&#xD;
          4. Expired air carbon monoxide (CO) ≥10 ppm.&#xD;
&#xD;
          5. Able to swallow multiple tablets at one time.&#xD;
&#xD;
          6. Able to fully understand, comply with all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion&#xD;
        into the study at screening.&#xD;
&#xD;
          1. Known hypersensitivity to cytisine or any of the excipients.&#xD;
&#xD;
          2. Known severe hypersensitivity to any other drug.&#xD;
&#xD;
          3. Positive urinary drugs of abuse screen, determined within 28 days before&#xD;
             cytisine/placebo dosing.&#xD;
&#xD;
          4. Positive ethanol breath test.&#xD;
&#xD;
          5. Clinically significant abnormal serum chemistry, hematology, coagulation or urinalysis&#xD;
             values within 28 days of randomization (i.e. requiring treatment or monitoring).&#xD;
&#xD;
          6. Clinically significant abnormalities in 12-lead echocardiogram (ECG) determined after&#xD;
             minimum of 5 minutes in supine position within 28 days of randomization (i.e.&#xD;
             requiring treatment or further assessment).&#xD;
&#xD;
          7. Body Mass Index (BMI) classification for being underweight (&lt;18.5 kg/m2) or having&#xD;
             ≥Class 2 obesity (≥35 kg/m2).&#xD;
&#xD;
          8. History of acute myocardial infarction, unstable angina, stroke, cerebrovascular&#xD;
             incident, cardiac arrhythmia, or hospitalization for congestive heart failure.&#xD;
&#xD;
          9. Blood pressure ≥160/100 mmHg, measured on the dominant arm, after at least 3 minutes&#xD;
             in supine position.&#xD;
&#xD;
         10. Creatinine clearance (CrCl) &lt;80 mL/min (estimated with the Cockroft-Gault equation).&#xD;
&#xD;
         11. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.0 x the upper&#xD;
             limit of normal (ULN).&#xD;
&#xD;
         12. Any inability to comply with study restrictions (See Section 9)&#xD;
&#xD;
         13. Any inability or difficulty in fasting.&#xD;
&#xD;
         14. Difficulty in donating blood on either arm.&#xD;
&#xD;
         15. If woman of childbearing potential, positive result in serum beta-human chorionic&#xD;
             gonadotropin (hCG) pregnancy test.&#xD;
&#xD;
         16. Women who are breast-feeding.&#xD;
&#xD;
         17. Subjects who do not agree to use acceptable methods of birth control during the study&#xD;
             (See Section 9.4).&#xD;
&#xD;
         18. Participation in a clinical study with an investigational drug within the previous 2&#xD;
             months.&#xD;
&#xD;
         19. Participation in more than 2 clinical trials within the previous 12 months.&#xD;
&#xD;
         20. Any other reason that the investigator views the subject should not participate or&#xD;
             would be unable to fulfill the requirements for the study.&#xD;
&#xD;
             Subjects meeting ANY of the following exclusion criteria will NOT be eligible for&#xD;
             inclusion into the study at admission to each cohort.&#xD;
&#xD;
         21. Any recent disease or condition or treatment that, according to the Investigator,&#xD;
             would put the subject at undue risk due to study participation.&#xD;
&#xD;
         22. Positive urinary drugs of abuse screen.&#xD;
&#xD;
         23. Positive ethanol breath test.&#xD;
&#xD;
         24. If female of childbearing potential, positive result in urine beta-hCG pregnancy test.&#xD;
&#xD;
         25. Any other reason that the investigator views the subject should not participate or&#xD;
             would be unable to fulfill the requirements for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene Fonseca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital da Prelada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BlueClinical</name>
      <address>
        <city>Porto</city>
        <zip>4250-449</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <results_first_submitted>August 26, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03848208/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03848208/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in a single center in Portugal.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned to receive a single oral dose of cytisine or placebo in a 3:1 ratio (6 cytisine:2 placebo) for each dose cohort. Seventy-four (74) participants were randomized; 2 were withdrawn from the study by physician decision before dosing (1 due to high blood pressure and 1 due to noncompliance with protocol restrictions).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo to match Cytisine 6-30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P2">
          <title>Cytisine 6 mg</title>
          <description>Cytisine 6 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P3">
          <title>Cytisine 9 mg</title>
          <description>Cytisine 9 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P4">
          <title>Cytisine 12 mg</title>
          <description>Cytisine 12 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P5">
          <title>Cytisine 15 mg</title>
          <description>Cytisine 15 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P6">
          <title>Cytisine 18 mg</title>
          <description>Cytisine 18 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P7">
          <title>Cytisine 21 mg</title>
          <description>Cytisine 21 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P8">
          <title>Cytisine 24 mg</title>
          <description>Cytisine 24 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P9">
          <title>Cytisine 27 mg</title>
          <description>Cytisine 27 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="P10">
          <title>Cytisine 30 mg</title>
          <description>Cytisine 30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo to match Cytisine 6-30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B2">
          <title>Cytisine 6 mg</title>
          <description>Cytisine 6 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B3">
          <title>Cytisine 9 mg</title>
          <description>Cytisine 9 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B4">
          <title>Cytisine 12 mg</title>
          <description>Cytisine 12 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B5">
          <title>Cytisine 15 mg</title>
          <description>Cytisine 15 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B6">
          <title>Cytisine 18 mg</title>
          <description>Cytisine 18 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B7">
          <title>Cytisine 21 mg</title>
          <description>Cytisine 21 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B8">
          <title>Cytisine 24 mg</title>
          <description>Cytisine 24 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B9">
          <title>Cytisine 27 mg</title>
          <description>Cytisine 27 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B10">
          <title>Cytisine 30 mg</title>
          <description>Cytisine 30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="7.5"/>
                    <measurement group_id="B2" value="44.5" spread="12.1"/>
                    <measurement group_id="B3" value="35.7" spread="8.2"/>
                    <measurement group_id="B4" value="35.3" spread="11.1"/>
                    <measurement group_id="B5" value="34.7" spread="7.5"/>
                    <measurement group_id="B6" value="37.8" spread="12.9"/>
                    <measurement group_id="B7" value="30.3" spread="8.1"/>
                    <measurement group_id="B8" value="30.0" spread="5.5"/>
                    <measurement group_id="B9" value="30.3" spread="4.6"/>
                    <measurement group_id="B10" value="29.7" spread="8.9"/>
                    <measurement group_id="B11" value="33.5" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Races</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have to have a causal relationship with the treatment. A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; or is an important medical event which requires medical intervention to prevent one of the above. Treatment emergent events are those that occurred after the first dose of study drug.</description>
        <time_frame>From first dose of study drug through Day 6</time_frame>
        <population>Safety Set: all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo to match Cytisine 6-30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Cytisine 6 mg</title>
            <description>Cytisine 6 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Cytisine 9 mg</title>
            <description>Cytisine 9 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Cytisine 12 mg</title>
            <description>Cytisine 12 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Cytisine 15 mg</title>
            <description>Cytisine 15 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Cytisine 18 mg</title>
            <description>Cytisine 18 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O7">
            <title>Cytisine 21 mg</title>
            <description>Cytisine 21 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O8">
            <title>Cytisine 24 mg</title>
            <description>Cytisine 24 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O9">
            <title>Cytisine 27 mg</title>
            <description>Cytisine 27 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O10">
            <title>Cytisine 30 mg</title>
            <description>Cytisine 30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have to have a causal relationship with the treatment. A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; or is an important medical event which requires medical intervention to prevent one of the above. Treatment emergent events are those that occurred after the first dose of study drug.</description>
          <population>Safety Set: all participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Study Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set: all participants who received a dose of cytisine and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cytisine 6 mg</title>
            <description>Cytisine 6 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Cytisine 9 mg</title>
            <description>Cytisine 9 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Cytisine 12 mg</title>
            <description>Cytisine 12 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Cytisine 15 mg</title>
            <description>Cytisine 15 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Cytisine 18 mg</title>
            <description>Cytisine 18 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Cytisine 21 mg</title>
            <description>Cytisine 21 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O7">
            <title>Cytisine 24 mg</title>
            <description>Cytisine 24 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O8">
            <title>Cytisine 27 mg</title>
            <description>Cytisine 27 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O9">
            <title>Cytisine 30 mg</title>
            <description>Cytisine 30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)</title>
          <population>Pharmacokinetic Analysis Set: all participants who received a dose of cytisine and had evaluable pharmacokinetic data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.05" lower_limit="56.07" upper_limit="86.03"/>
                    <measurement group_id="O2" value="93.62" lower_limit="79.44" upper_limit="107.79"/>
                    <measurement group_id="O3" value="94.27" lower_limit="74.87" upper_limit="113.66"/>
                    <measurement group_id="O4" value="126.45" lower_limit="100.82" upper_limit="152.07"/>
                    <measurement group_id="O5" value="134.94" lower_limit="107.00" upper_limit="162.88"/>
                    <measurement group_id="O6" value="150.08" lower_limit="114.12" upper_limit="186.04"/>
                    <measurement group_id="O7" value="171.44" lower_limit="149.31" upper_limit="193.57"/>
                    <measurement group_id="O8" value="151.05" lower_limit="122.01" upper_limit="180.08"/>
                    <measurement group_id="O9" value="166.65" lower_limit="120.95" upper_limit="212.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Time to Occurrence of Cmax (Tmax)</title>
        <time_frame>Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set: all participants who received a dose of cytisine and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cytisine 6 mg</title>
            <description>Cytisine 6 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Cytisine 9 mg</title>
            <description>Cytisine 9 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Cytisine 12 mg</title>
            <description>Cytisine 12 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Cytisine 15 mg</title>
            <description>Cytisine 15 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Cytisine 18 mg</title>
            <description>Cytisine 18 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Cytisine 21 mg</title>
            <description>Cytisine 21 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O7">
            <title>Cytisine 24 mg</title>
            <description>Cytisine 24 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O8">
            <title>Cytisine 27 mg</title>
            <description>Cytisine 27 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
          <group group_id="O9">
            <title>Cytisine 30 mg</title>
            <description>Cytisine 30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time to Occurrence of Cmax (Tmax)</title>
          <population>Pharmacokinetic Analysis Set: all participants who received a dose of cytisine and had evaluable pharmacokinetic data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.38" lower_limit="0.83" upper_limit="2.50"/>
                    <measurement group_id="O3" value="1.88" lower_limit="1.25" upper_limit="2.50"/>
                    <measurement group_id="O4" value="1.88" lower_limit="0.50" upper_limit="2.50"/>
                    <measurement group_id="O5" value="2.00" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O6" value="1.89" lower_limit="1.25" upper_limit="3.00"/>
                    <measurement group_id="O7" value="2.50" lower_limit="0.83" upper_limit="3.00"/>
                    <measurement group_id="O8" value="2.75" lower_limit="1.75" upper_limit="3.00"/>
                    <measurement group_id="O9" value="2.50" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug through Day 6</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo to match Cytisine 6-30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E2">
          <title>Cytisine 6 mg</title>
          <description>Cytisine 6 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E3">
          <title>Cytisine 9 mg</title>
          <description>Cytisine 9 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E4">
          <title>Cytisine 12 mg</title>
          <description>Cytisine 12 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E5">
          <title>Cytisine 15 mg</title>
          <description>Cytisine 15 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E6">
          <title>Cytisine 18 mg</title>
          <description>Cytisine 18 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E7">
          <title>Cytisine 21 mg</title>
          <description>Cytisine 21 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E8">
          <title>Cytisine 24 mg</title>
          <description>Cytisine 24 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E9">
          <title>Cytisine 27 mg</title>
          <description>Cytisine 27 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
        <group group_id="E10">
          <title>Cytisine 30 mg</title>
          <description>Cytisine 30 mg administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 21.1">Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Cain, Vice President, Clinical Research</name_or_title>
      <organization>Achieve Life Sciences</organization>
      <phone>425.686.1546</phone>
      <email>dcain@achievelifesciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

